text:
Gay Men: Practice Interventions
Robert L. Miller Jr.
This chapter explores salient concepts of social work practice with gay men. These concepts are described within a life cycle context. The illuminated concepts have been identified based on the biopsychosocial and spiritual developments in the social work literature related to this population since the printing of the 19th edition of the Encyclopedia of Social Work.
Human Needs: Family
Ruth Paris and Ellen R. DeVoe
In this entry we address the primary purpose of family in supporting the growth and development of individual members throughout the life course. Life cycle and attachment theories inform our understanding of how families function. Changing family patterns are addressed in terms of the variety of family forms, the multiplicity of needs as economies shift and life expectancy lengthens, family coping and adaptation to normative transitions and unexpected crises, and the influence of cultural and racial diversity. We conclude with brief comments on the issues for contemporary families and needs for the social work profession.
Lesbians: Practice Interventions
Deana F. Morrow
This entry will provide an overview of psychosocial issues and social work intervention relevant to working with lesbians. Practice issues related to the impact of heterosexism, coming out, lesbian identity development, and lesbian couple and family formation will be discussed. Assessment and intervention methods appropriate for social work practice with lesbians will be addressed.
Eun-Kyoung Othelia Lee and Ruth McRoy
This entry defines the concept of multiculturalism and explains, from a historical and contemporary perspective, its evolution and significance in social work. The relationship between multiculturalism and socioeconomic justice, oppression, populations at risk, health disparities, and discrimination is explained. The importance of preparatory training for social workers to meet the challenges of multiculturalism is highlighted and examples of cross-cultural training models are provided. Implications of multiculturalism for clinical practice and policy development are discussed.
Queer Communities (Competency and Positionality)
Michael P. Dentato
This entry discusses the critical and ongoing need for the expansion of competency related to understanding queer identities and issues related to positionality within queer communities. It will examine the evolving terminology and context through which the term "queer" has been defined over the years and relevant challenges with connectedness to the lesbian, gay, bisexual, and transgender community. Age cohort associations and the role of intersectionality will also be explored to underscore the multidimensional discourse necessary to build effective competency with queer communities. Last, this entry will examine implications for best practices related to establishing and maintaining an affirming therapeutic alliance between queer clients and social-work practitioners, as well as the continued need for research related to queer identities and the queer community.
Transgender People
M. J. Gilbert
In this entry, transgender is defined in the context of ethnomethodology and social construction of gender. A history of the role of transgender people in the gay, lesbian, and bisexual rights movement is presented, including tensions concerning the role of transgender people in this movement. Issues regarding social work practice related to transgender issues on the micro, mezzo, macro, and meta levels are discussed.
Women, Development, and Gender Inequality
Lena Dominelli
Women have a lengthy history of fighting their oppression as women and the inequalities associated with this to claim their place on the world stage, in their countries, and within their families. This article focuses on women's struggles to be recognized as having legitimate concerns about development initiatives at all levels of society and valuable contributions to make to social development. Crucial to their endeavors were: (1) upholding gender equality and insisting that women be included in all deliberations about sustainable development and (2) seeing that their daily life needs, including their human rights, be treated with respect and dignity and their right to and need for education, health, housing, and all other public goods are realized. The role of the United Nations in these endeavors is also considered. Its policies on gender and development, on poverty alleviation strategies—including the Millennium Development Goals and the Sustainable Development Goals—are discussed and critiqued. Women's rights are human rights, but their realization remains a challenge for policymakers and practitioners everywhere. Social workers have a vital role to play in advocating for gender equality and mobilizing women to take action in support of their right to social justice. Our struggle for equality has a long and courageous history.
Women's Health
Vimla Nadkarni and Roopashri Sinha
The entry outlines a historical and global overview of women's health in the context of human rights and public health activism. It unravels social myths, traditional norms, and stereotypes impacting women's health because social workers must understand the diverse factors affecting women's health in a continually changing and globalized world. There is need for more inclusive feminist and human rights models to study and advocate women's health. There is as much scope for working with women in a more holistic manner as there is for researching challenging issues and environments shaping women's health.


text:
|Clinical data
|Trade names
|Cymbalta, many others[1]
|License data
|Routes of
|ATC code
|Legal status
|Legal status
|Pharmacokinetic data
|~ 50% (32% to 80%)
|Protein binding
|~ 95%
|Liver, two P450 isozymes, CYP2D6 and CYP1A2
|Biological half-life
|12.1 hours
|70% in urine, 20% in feces
|CAS Number
as HCl: 136434-34-9
|PubChem (CID)
as HCl: 9044SC542W
|PDB ligand ID
|29E (PDBe, RCSB PDB)
|ECHA InfoCard
|Chemical and physical data
|Molar mass
|297.41456 g/mol
|3D model (Jmol)
|Interactive image
|(what is this?) (verify)
Duloxetine, sold under the brand name Cymbalta among others,[1] is mostly prescribed for major depressive disorder, generalized anxiety disorder, fibromyalgia and neuropathic pain.[2]
It is a thiophene derivative and a selective neurotransmitter reuptake inhibitor for serotonin, norepinephrine, and to a lesser degree dopamine. It belongs to a class of heterocyclic antidepressants known as a serotonin–norepinephrine reuptake inhibitors (SNRI).[3]
Duloxetine failed to receive US approval for stress urinary incontinence amid concerns over liver toxicity and suicidal events; however, it was approved for this indication in the UK, where it is recommended as an add-on medication in stress urinary incontinence instead of surgery.[4] It was originally made by Eli Lilly.
Medical uses
The main uses of duloxetine are in major depressive disorder, generalized anxiety disorder, urinary incontinence, neuropathic pain, chronic musculoskeletal pain, and fibromyalgia.[2][5][6][7]
Duloxetine is recommended as a first line agent for the treatment of chemotherapy-induced neuropathy by the American Society of Clinical Oncology,[8] as a first-line therapy for fibromyalgia in the presence of mood disorders by the German Interdisciplinary Association for Pain Therapy,[9] as a Grade B recommendation for the treatment of diabetic neuropathy by the American Association for Neurology[10] and as a level A recommendation in certain neuropathic states by the European Federation of Neurological Societies.[11]
A 2014 Cochrane review concluded that duloxetine is beneficial in the treatment of diabetic neuropathy and fibromyalgia but that more comparative studies with other medicines are needed.[12] The French medical journal Prescrire concluded that duloxetine is no better than other available agents and has a greater risk of side effects.[13] Thus they recommend against its general use.[13]
Major depressive disorder
Duloxetine was approved for the treatment of major depression in 2004. While duloxetine has demonstrated improvement in depression-related symptoms compared to placebo, comparisons of duloxetine to other antidepressant medications have been less successful. A 2012 Cochrane Review did not find greater efficacy of duloxetine compared to SSRIs and newer antidepressants. Additionally, the review found evidence that duloxetine has increased side effects and reduced tolerability compared to other antidepressants. It thus did not recommend duloxetine as a first line treatment for major depressive disorder, given the high cost of duloxetine compared to off-patent antidepressants and lack of increased efficacy.[14] Generic duloxetine became available in 2013.[15]
Generalized anxiety disorder
Duloxetine is more effective than placebo in the treatment of generalized anxiety disorder (GAD).[16] Major guidelines such as Maudsley Prescribing Guidelines,[17] and Canadian Psychiatric Association Guidelines[18] do not list duloxetine among the recommended treatment options. However, a review from the Annals of Internal Medicine lists duloxetine among the first line drug treatments, along with citalopram, escitalopram, sertraline, paroxetine, and venlafaxine.[19]
Diabetic peripheral neuropathy
Duloxetine was approved for the pain associated with diabetic peripheral neuropathy (DPN), based on the positive results of two clinical trials. The average daily pain was measured using an 11-point scale, and duloxetine treatment resulted in an additional 1–1.7 points decrease of pain as compared with placebo.[20][21][22] At least 50% pain relief was achieved in 40–45% of the duloxetine patients vs. 20–22% of placebo patients. Pain decreased by more than 90%, in 9–14% of duloxetine patients vs. 2–4% of placebo patients. Most of the response was achieved in the first two weeks on the medication. Duloxetine slightly increased the fasting serum glucose; however this effect was deemed to be of "minimal clinical significance".[20]
The comparative efficacy of duloxetine and established pain-relief medications for DPN is unclear. A systematic review noted that tricyclic antidepressants (imipramine and amitriptyline), traditional anticonvulsants and opioids have better efficacy than duloxetine. Duloxetine, tricyclic antidepressants and anticonvulsants have similar tolerability while the opioids caused more side effects.[23] Another review in Prescrire International considered the moderate pain relief achieved with duloxetine to be clinically insignificant and the results of the clinical trials unconvincing. The reviewer saw no reason to prescribe duloxetine in practice.[24] The comparative data collected by reviewers in BMC Neurology indicated that amitriptyline, other tricyclic antidepressants and venlafaxine may be more effective. However, the authors noted that the evidence in favor of duloxetine is much more solid.[25] A Cochrane review concluded that the evidence in support of duloxetine's efficacy in treating painful diabetic neuropathy was adequate, and that further trials should focus on comparisons with other medications.[12]
Fibromyalgia and chronic pain
A review of duloxetine found that it reduced pain and fatigue, and improved physical and mental performance compared to placebo.[26]
The U.S. Food and Drug Administration (FDA) regulators approved the drug for the treatment of fibromyalgia in June 2008.[27]
It may be useful for chronic pain from osteoarthritis.[28][29]
On November 4, 2010, the U.S. Food and Drug Administration approved duloxetine to treat chronic musculoskeletal pain, including discomfort from osteoarthritis and chronic lower back pain.[30]
Stress urinary incontinence
Duloxetine was first reported to improve outcomes in stress incontinence (SUI) in 1998.[31] The safety and utility of duloxetine in the treatment of incontinence has been evaluated in a series of meta analyses and practice guidelines.
- A 2013 meta-analysis concluded that duloxetine decreased incontinence episodes more than placebo with people about 56% more likely than placebo to experience a 50% decrease in episodes. Adverse effects were experienced by 83% of duloxetine-treated subjects and by 45% of placebo-treated subjects.[32]
- A 2012 review and practice guideline published by the European Association of Urology concluded that the clinical trial data provides Grade 1a evidence that duloxetine improves but does not cure urinary incontinence, and that it causes a high rate of gastrointestinal side effects (mainly nausea and vomiting) leading to a high rate of treatment discontinuation.[33]
- The National Institute for Clinical and Health Excellence recommends (as of September 2013) that duloxetine not be routinely offered as first line treatment, and that it only be offered as second line therapy in women wishing to avoid therapy. The guideline further states that women should be counseled regarding the drug's side effects.[34]
The following contraindications are listed by the manufacturer:[35]
- Hypersensitivity: duloxetine is contraindicated in patients with a known hypersensitivity to duloxetine or any of the inactive ingredients.
- Monoamine oxidase inhibitors (MAOIs): concomitant use in patients taking MAOIs is contraindicated.
- Uncontrolled narrow-angle glaucoma: in clinical trials, Cymbalta use was associated with an increased risk of mydriasis (dilation of the pupil); therefore, its use should be avoided in patients with uncontrolled narrow-angle glaucoma, in which mydriasis can cause sudden worsening.
- Central nervous system (CNS) acting drugs: given the primary CNS effects of duloxetine, it should be used with caution when it is taken in combination with or substituted for other centrally acting drugs, including those with a similar mechanism of action.
- Duloxetine and thioridazine should not be co-administered.
In addition, the FDA has reported on life-threatening drug interactions that may be possible when co-administered with triptans and other drugs acting on serotonin pathways leading to increased risk for serotonin syndrome.[36]
Adverse effects
Nausea, somnolence, insomnia, and dizziness are the main side effects, reported by about 10% to 20% of patients.[37]
In a trial for major depressive disorder (MDD), the most commonly reported treatment-emergent adverse events among duloxetine-treated patients were nausea (34.7%), dry mouth (22.7%), headache (20.0%) and dizziness (18.7%), and except for headache, these were reported significantly more often than in the placebo group.[38] In a long-term study of fibromyalgia patients receiving duloxetine, frequency and type of adverse effects was similar to that reported in the MDD above. Side effects tended to be mild-to-moderate, and tended to decrease in intensity over time.[39]
Sexual dysfunction is often a side effect of drugs that inhibit serotonin reuptake. Specifically, common side effects include difficulty becoming aroused, lack of interest in sex, and anorgasmia (trouble achieving orgasm). Loss of or decreased response to sexual stimuli and ejaculatory anhedonia are also possible. Frequency of treatment-emergent sexual dysfunction in long-term treatment has been found to be similar for duloxetine and SSRIs when compared in clinical trials,[40][41] while there is some evidence that duloxetine is associated with less sexual dysfunction than escitalopram when measured at 4 and 8 weeks of treatment.[41]
Postmarketing spontaneous reports
Reported adverse events which were temporally correlated to duloxetine therapy include rash, reported rarely, and the following adverse events, reported very rarely: alanine aminotransferase increased, alkaline phosphatase increased, anaphylactic reaction, angioneurotic edema, aspartate aminotransferase increased, bilirubin increased, glaucoma, hepatotoxicity, hyponatremia, jaundice, orthostatic hypotension (especially at the initiation of treatment), Stevens–Johnson syndrome, syncope (especially at initiation of treatment), and urticaria.[42]
Discontinuation syndrome
During marketing of other SSRIs and SNRIs, there have been spontaneous reports of adverse events occurring upon discontinuation of these drugs, particularly when abrupt, including the following: dysphoric mood, irritability, agitation, dizziness, sensory disturbances (e.g., paresthesias such as brain zap electric shock sensations), anxiety, confusion, headache, lethargy, emotional lability, insomnia, hypomania, tinnitus, and seizures. The withdrawal syndrome from duloxetine resembles the SSRI discontinuation syndrome.
When discontinuing treatment with duloxetine, the manufacturer recommends a gradual reduction in the dose, rather than abrupt cessation, whenever possible. If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered. Subsequently, the physician may continue decreasing the dose but at a more gradual rate.
In placebo-controlled clinical trials of up to nine weeks' duration of patients with MDD, a systematic evaluation of discontinuation symptoms in patients taking duloxetine following abrupt discontinuation found the following symptoms occurring at a rate greater than or equal to 2% and at a significantly higher rate in duloxetine-treated patients compared to those discontinuing from placebo: dizziness, nausea, headache, paresthesia, vomiting, irritability, and nightmare.[43]
The FDA requires all antidepressants, including duloxetine, to carry a black box warning stating that antidepressants may increase the risk of suicide in persons younger than 25. This warning is based on statistical analyses conducted by two independent groups of the FDA experts that found a 2-fold increase of the suicidal ideation and behavior in children and adolescents, and 1.5-fold increase of suicidality in the 18–24 age group.[44][45][46]
To obtain statistically significant results the FDA had to combine the results of 295 trials of 11 antidepressants for psychiatric indications. As suicidal ideation and behavior in clinical trials are rare, the results for any drug taken separately usually do not reach statistical significance.
In 2005 the United States FDA released a public health advisory noting that there had been 11 reports of suicide attempts and 3 reports of suicidality within the mostly middle-aged women participating in the open label extension trials of duloxetine for the treatment of stress urinary incontinence. The FDA described the potential role of confounding social stressors "unclear". The suicide attempt rate in the SUI study population (based on 9,400 patients) was calculated to be 400 per 100,000 person years. This rate is greater than the suicide attempt rate among middle-aged U.S. women that has been reported in published studies, i.e., 150 to 160 per 100,000 person years. In addition, one death from suicide was reported in a Cymbalta clinical pharmacology study in a healthy female volunteer without SUI. No increase in suicidality was reported in controlled trials of Cymbalta for depression or diabetic neuropathic pain.[47]
Mechanism of action
|Ki (nM)
Duloxetine inhibits the reuptake of serotonin and norepinephrine (NE) in the central nervous system. Duloxetine increases dopamine (DA) specifically in the prefrontal cortex, where there are few DA reuptake pumps, via the inhibition of NE reuptake pumps (NET) which is believed to mediate reuptake of DA and NE.[49] However, duloxetine has no significant affinity for dopaminergic, cholinergic, histaminergic, opioid, glutamate, and GABA reuptake transporters and can therefore be considered to be a selective reuptake inhibitor at the 5-HT and NE transporters. Duloxetine undergoes extensive metabolism, but the major circulating metabolites do not contribute significantly to the pharmacologic activity.[50][51]
Major depressive disorder is believed to be due in part to an increase in pro-inflammatory cytokines within the central nervous system. Antidepressants including ones with a similar mechanism of action as duloxetine, i.e. serotonin metabolism inhibition, cause a decrease in proinflammatory cytokine activity and an increase in anti-inflammatory cytokines; this mechanism may apply to duloxetine in its effect on depression but research on cytokines specific to duloxetine therapy is lacking.[52]
The analgesic properties of duloxetine in the treatment of diabetic neuropathy and central pain syndromes such as fibromyalgia are believed to be due to sodium ion channel blockade.[53]
Absorption: Duloxetine is acid labile, and is formulated with enteric coating to prevent degradation in the stomach. Duloxetine has good oral bioavailability, averaging 50% after one 60 mg dose. There is an average 2-hour lag until absorption begins with maximum plasma concentrations occurring about 6 hours post dose. Food does not affect the Cmax of duloxetine, but delays the time to reach peak concentration from 6 to 10 hours.[51]
Distribution: Duloxetine is highly bound (>90%) to proteins in human plasma, binding primarily to albumin and α1-acid glycoprotein. Volume of distribution is 1640L.[54]
Metabolism: Duloxetine undergoes predominately hepatic metabolism via two cytochrome P450 isozymes, CYP2D6 and CYP1A2. Circulating metabolites are pharmacologically inactive.[54]
Elimination: Duloxetine has an elimination half-life of about 12 hours (range 8 to 17 hours) and its pharmacokinetics are dose proportional over the therapeutic range. Steady-state is usually achieved after 3 days. Only trace amounts (<1%) of unchanged duloxetine are present in the urine and most of the dose (approx. 70%) appears in the urine as metabolites of duloxetine with about 20% excreted in the feces.[54]
Duloxetine was created by Lilly researchers. David Robertson; David Wong, a co-discoverer of fluoxetine; and Joseph Krushinski are listed as inventors on the patent application filed in 1986 and granted in 1990.[55] The first publication on the discovery of the racemic form of duloxetine known as LY227942, was made in 1988.[56] The (+)-enantiomer of LY227942, assigned LY248686, was chosen for further studies, because it inhibited serotonin reuptake in rat synaptosomes to twice the degree of the (–)-enantiomer. This molecule was subsequently named duloxetine.[57]
In 2001, Lilly filed a New Drug Application (NDA) for duloxetine with the US Food and Drug Administration. However, in 2003, the FDA "recommended this application as not approvable from the manufacturing and control standpoint" because of "significant cGMP (current Good Manufacturing Practice) violations at the finished product manufacturing facility" of Eli Lilly in Indianapolis. Additionally, "potential liver toxicity" and QTc interval prolongation appeared as a concern. The FDA experts concluded that "duloxetine can cause hepatotoxicity in the form of transaminase elevations. It may also be a factor in causing more severe liver injury, but there are no cases in the NDA database that clearly demonstrate this. Use of duloxetine in the presence of ethanol may potentiate the deleterious effect of ethanol on the liver." The FDA also recommended "routine blood pressure monitoring" at the new highest recommended dose of 120 mg, "where 24% patients had one or more blood pressure readings of 140/90 vs. 9% of placebo patients."[58]
After the manufacturing issues were resolved, the liver toxicity warning included in the prescribing information, and the follow-up studies showed that duloxetine does not cause QTc interval prolongation, duloxetine was approved by the FDA for depression and diabetic neuropathy in 2004.[59] In 2007, Health Canada approved duloxetine for the treatment of depression and diabetic peripheral neuropathic pain.[60]
Duloxetine was approved for use of stress urinary incontinence (SUI) in the EU in 2004. In 2005, Lilly withdrew the duloxetine application for stress urinary incontinence (SUI) in the U.S., stating that discussions with the FDA indicated "the agency is not prepared at this time to grant approval ... based on the data package submitted." A year later Lilly abandoned the pursuit of this indication in the U.S. market.[61][62]
The FDA approved duloxetine for the treatment of generalized anxiety disorder in February 2007.[63]
Cymbalta generated sales of nearly $5 billion in 2012 with $4 billion of that in the U.S., but its patent protection terminated January 1, 2014. Lilly received a six-month extension beyond June 30, 2013 after testing for the treatment of depression in adolescents, which may produce $1.5 billion in added sales.[64][65]
The first generic duloxetine was marketed by Dr. Reddy.[66]
Brand names
Duloxetine is marketed under many brand names worldwide.[1]
- 1 2 3 Drugs.com International duloxetine brands Page accessed March 10, 2016
- 1 2 "Duloxetine". Monograph. The American Society of Health-System Pharmacists. Retrieved 2015-02-26.
- ↑ "MeSH Browser". meshb.nlm.nih.gov. Retrieved 2016-11-28.
- ↑ National Institute for Health and Clinical Excellence. Clinical guideline 40: Urinary incontinence. London, 2006.
- ↑ National Institute for Health and Clinical Excellence. Clinical guideline 96: Neuropathic pain - pharmacological management. London, 2010.
- ↑ Bril V, England J, Franklin GM, et al. (2011). "Evidence-based guideline: Treatment of painful diabetic neuropathy". Neurology. Online (20): 1758–65. doi:10.1212/WNL.0b013e3182166ebe. PMC 3100130. PMID 21482920.
- ↑ "Cymbalta (duloxetine hydrochloride) Delayed-Release Capsules for Oral Use." (PDF).
- ↑ Hershman DL, Lacchetti C, Dworkin RH, et al. (June 2014). "Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline". J. Clin. Oncol. 32 (18): 1941–67. doi:10.1200/JCO.2013.54.0914. PMID 24733808.
- ↑ Sommer C, Häuser W, Alten R, et al. (June 2012). "[Drug therapy of fibromyalgia syndrome. Systematic review, meta-analysis and guideline]". Schmerz (in German). 26 (3): 297–310. doi:10.1007/s00482-012-1172-2. PMID 22760463.
- ↑ Bril V, England JD, Franklin GM, et al. (June 2011). "Evidence-based guideline: treatment of painful diabetic neuropathy--report of the American Association of Neuromuscular and Electrodiagnostic Medicine, the American Academy of Neurology, and the American Academy of Physical Medicine & Rehabilitation". Muscle Nerve. 43 (6): 910–7. doi:10.1002/mus.22092. PMID 21484835.
- ↑ Attal N, Cruccu G, Baron R, et al. (September 2010). "EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision". Eur. J. Neurol. 17 (9): 1113–e88. doi:10.1111/j.1468-1331.2010.02999.x. PMID 20402746.
- 1 2 Lunn MP, Hughes RA, Wiffen PJ (2014). "Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia". Cochrane Database Syst Rev. 1: CD007115. doi:10.1002/14651858.CD007115.pub3. PMID 24385423.
- 1 2 "Towards better patient care: drugs to avoid in 2014". Prescrire International. 23 (150): 161–165. June 2014. PMID 25121155.
- ↑ Cipriani, A; Koesters, M; Furukawa, TA; Nosè, M; Purgato, M; Omori, IM; Trespidi, C; Barbui, C (Oct 17, 2012). "Duloxetine versus other anti-depressive agents for depression". The Cochrane database of systematic reviews. 10: CD006533. doi:10.1002/14651858.cd006533.pub2. PMC 4169791. PMID 23076926.
- ↑ Swiatek, Jeff (2013-10-13). "Loss of Cymbalta patent a major blow for Eli Lilly". Indianapolis Star. Retrieved 2015-02-27.
- ↑ Carter, NJ; McCormack, PL (2009). "Duloxetine: a review of its use in the treatment of generalized anxiety disorder.". CNS Drugs. 23 (6): 523–41. doi:10.2165/00023210-200923060-00006. PMID 19480470.
- ↑ Kerwin, Robert; Taylor, David H.; Carol Paton (2007). Maudsley Prescribing Guidelines. Informa Healthcare. p. 254. ISBN 0-415-42416-X.
- ↑ Canadian Psychiatric, Association (July 2006). "Clinical practice guidelines. Management of anxiety disorders". Can J Psychiatry. 51 (8 Suppl 2): 52S–55S. PMID 16933543.
- ↑ Patel, G; Fancher, TL (Dec 3, 2013). "In the clinic. Generalized anxiety disorder.". Annals of Internal Medicine. 159 (11): ITC6–1, ITC6–2, ITC6–3, ITC6–4, ITC6–5, ITC6–6, ITC6–7, ITC6–8, ITC6–9, ITC6–10, ITC6–11; quiz ITC6–12. doi:10.7326/0003-4819-159-11-201312030-01006. PMID 24297210.
- 1 2 Josefberg H (2004-09-03). "Application number 21-733. Medical review(s)." (PDF). FDA. Retrieved 2009-04-14.
- ↑ Goldstein DJ, Lu Y, Detke MJ, Lee TC, Iyengar S; Lu; Detke; Lee; Iyengar (July 2005). "Duloxetine vs. placebo in patients with painful diabetic neuropathy". Pain. 116 (1–2): 109–18. doi:10.1016/j.pain.2005.03.029. PMID 15927394.
- ↑ Raskin J, Pritchett YL, Wang F, et al. (2005). "A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain". Pain Med. 6 (5): 346–56. doi:10.1111/j.1526-4637.2005.00061.x. PMID 16266355.
- ↑ Wong MC, Chung JW, Wong TK; Chung; Wong (July 2007). "Effects of treatments for symptoms of painful diabetic neuropathy: systematic review". BMJ. 335 (7610): 87. doi:10.1136/bmj.39213.565972.AE. PMC 1914460. PMID 17562735.
- ↑ "Duloxetine: new indication. Depression and diabetic neuropathy: too many adverse effects". Prescrire Int. 15 (85): 168–72. October 2006. PMID 17121211.
- ↑ Sultan A, Gaskell H, Derry S, Moore RA; Gaskell; Derry; Moore (2008). "Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials". BMC Neurol. 8: 29. doi:10.1186/1471-2377-8-29. PMC 2529342. PMID 18673529.
- ↑ Acuna C (October 2008). "Duloxetine for the treatment of fibromyalgia". Drugs Today. 44 (10): 725–34. doi:10.1358/dot.2008.44.10.1269675. PMID 19137126.
- ↑ "FDA Approves Cymbalta for the Management of Fibromyalgia". Eli Lilly Co. 2008-06-16. Retrieved 2008-06-17.
- ↑ Citrome, L; Weiss-Citrome, A (Jan 2012). "A systematic review of duloxetine for osteoarthritic pain: what is the number needed to treat, number needed to harm, and likelihood to be helped or harmed?". Postgraduate Medicine. 124 (1): 83–93. doi:10.3810/pgm.2012.01.2521. PMID 22314118.
- ↑ Myers, J; Wielage, R. C.; Han, B; Price, K; Gahn, J; Paget, M. A.; Happich, M (2014). "The efficacy of duloxetine, non-steroidal anti-inflammatory drugs, and opioids in osteoarthritis: A systematic literature review and meta-analysis". BMC Musculoskeletal Disorders. 15: 76. doi:10.1186/1471-2474-15-76. PMC 4007556. PMID 24618328.
- ↑ "FDA clears Cymbalta to treat chronic musculoskeletal pain". FDA Press Announcements. Food and Drug Administration. 4 November 2010. Retrieved 19 August 2013.
- ↑ Voelker R (September 1998). "International group seeks to dispel incontinence "taboo"". JAMA. 280 (11): 951–3. doi:10.1001/jama.280.11.951. PMID 9749464.
- ↑ Li J, Yang L, Pu C, Tang Y, Yun H, Han P; Yang; Pu; Tang; Yun; Han (June 2013). "The role of duloxetine in stress urinary incontinence: a systematic review and meta-analysis". Int Urol Nephrol. 45 (3): 679–86. doi:10.1007/s11255-013-0410-6. PMID 23504618.
- ↑ "www.uroweb.org" (PDF).
- ↑ "Urinary incontinence Introduction CG171".
- ↑ "Eli Lilly and Company".
- ↑ Report a Serious Problem (2013-08-14). "Information for Healthcare Professionals: Duloxetine (marketed as Cymbalta) - Selective Serotonin Reuptake Inhibitors (SSRIs) or Selective Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) and 5-Hydroxytryptamine Receptor Agonists (Triptans)". Fda.gov. Retrieved 2013-09-18.
- ↑ Cymbalta package insert. Indianapolis, IN: Eli Lilly Pharmaceuticals; 2004, September.
- ↑ Perahia DG, Kajdasz DK, Walker DJ, Raskin J, Tylee A; Kajdasz; Walker; Raskin; Tylee (May 2006). "Duloxetine 60 mg once daily in the treatment of milder major depressive disorder". Int. J. Clin. Pract. 60 (5): 613–20. doi:10.1111/j.1368-5031.2006.00956.x. PMC 1473178. PMID 16700869.
- ↑ Chappell; Littlejohn, Kajdasz, Scheinberg, D'Souza, Moldofsky (Jun 2009). "A 1-year safety and efficacy study of duloxetine in patients with fibromyalgia". Clinical Journal of Pain. 25 (5): 365–375. doi:10.1097/ajp.0b013e31819be587. PMID 19454869.
- ↑ Duenas, H; Brnabic, Lee, Montejo, Prakash, Casimiro-Querubin, Khaled, Dossenbach, Raskin (Nov 2011). "Treatment-emergent sexual dysfunction with SSRIs and duloxetine: efferctiveness and functional outcomes over a 6-month observational period". International Journal of Psychiatry in Clinical Practice. 15 (4): 242–254. doi:10.3109/13651501.2011.590209. PMID 22121997.
- 1 2 Clayton, A; Kornstein, Prakash, Mallinckrodt, Wohlreich (July 2007). "Changes in sexual functioning associated with duloxetine, escitalopram, and placebo in the treatment of patients with major depressive disorder". Journal of Sexual Medicine. 4 (4 Pt 1): 917–929. doi:10.1111/j.1743-6109.2007.00520.x. PMID 17627739.
- ↑ Duloxetine Side Effects, and Drug Interactions - RxList Monographs
- ↑ Perahia DG, Kajdasz DK, Desaiah D, Haddad PM; Kajdasz; Desaiah; Haddad (December 2005). "Symptoms following abrupt discontinuation of duloxetine treatment in patients with major depressive disorder". J Affect Disord. 89 (1–3): 207–12. doi:10.1016/j.jad.2005.09.003. PMID 16266753.
- ↑ Levenson M, Holland C. "Antidepressants and Suicidality in Adults: Statistical Evaluation. (Presentation at Psychopharmacologic Drugs Advisory Committee; December 13, 2006)". Retrieved 2007-05-13.
- ↑ Stone MB, Jones ML (2006-11-17). "Clinical review: relationship between antidepressant drugs and suicidality in adults" (PDF). Overview for December 13 Meeting of Psychopharmacologic Drugs Advisory Committee (PDAC). FDA. pp. 11–74. Retrieved 2007-09-22.
- ↑ Levenson M, Holland C (2006-11-17). "Statistical Evaluation of Suicidality in Adults Treated with Antidepressants" (PDF). Overview for December 13 Meeting of Psychopharmacologic Drugs Advisory Committee (PDAC). FDA. pp. 75–140. Retrieved 2007-09-22.
- ↑ "Historical Information on Duloxetine hydrochloride (marketed as Cymbalta)".
- ↑ Bymaster, FP; Dreshfield-Ahmad, LJ; Threlkeld, PG; Shaw, JL; Thompson, L; Nelson, DL; Hemrick-Luecke, SK; Wong, DT (December 2001). "Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors.". Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 25 (6): 871–80. doi:10.1016/S0893-133X(01)00298-6. PMID 11750180.
- ↑ Stahl, S. (2013). Stahl's essential pharmacology, 4th ed. Cambridge University Press, New York. p. 305, 308, 309.
- ↑ Stahl, SM; Grady, Moret, Briley (Sep 2005). "SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants". CNS Spectrums. 10 (9): 732–747. PMID 16142213.
- 1 2 Bymaster, FP; Lee, Knadler (2005). "The dual transporter inhibitor duloxetine: a review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depression". Curr Pharm Des. 11 (12): 1475–93. doi:10.2174/1381612053764805. PMID 15892657.
- ↑ De Berardis D, Conti CM, Serroni N, Moschetta FS, Olivieri L, Carano A, Salerno RM, Cavuto M, Farina B, Alessandrini M, Janiri L, Pozzi G, Di Giannantonio M; Conti; Serroni; Moschetta; Olivieri; Carano; Salerno; Cavuto; Farina; Alessandrini; Janiri; Pozzi; Di Giannantonio (2010). "The effect of newer serotonin-noradrenalin antidepressants on cytokine production: a review of the current literature". Int J Immunopathol Pharmacol. 23 (2): 417–22. PMID 20646337.
- ↑ Wang SY, Calderon J, Kuo Wang G; Calderon; Kuo Wang (September 2010). "Block of neuronal Na+ channels by antidepressant duloxetine in a state-dependent manner". Anesthesiology. 113 (3): 655–65. doi:10.1097/ALN.0b013e3181e89a93. PMID 20693878.
- 1 2 3 "Cymbalta product insert" (PDF).
- ↑ Robertson DW, Wong DT, Krushinski JH (1990-09-11). "United States Patent 4,956,388: 3-Aryloxy-3-substituted propanamines". USPTO. Retrieved 2008-05-17.
- ↑ Wong DT, Robertson DW, Bymaster FP, Krushinski JH, Reid LR; Robertson; Bymaster; Krushinski; Reid (1988). "LY227942, an inhibitor of serotonin and norepinephrine uptake: biochemical pharmacology of a potential antidepressant drug". Life Sci. 43 (24): 2049–57. doi:10.1016/0024-3205(88)90579-6. PMID 2850421.
- ↑ Bymaster FP, Beedle EE, Findlay J, et al. (December 2003). "Duloxetine (Cymbalta), a dual inhibitor of serotonin and norepinephrine reuptake". Bioorg. Med. Chem. Lett. 13 (24): 4477–80. doi:10.1016/j.bmcl.2003.08.079. PMID 14643350.
- ↑ "Approval package for: application number NDA 721-427. Administrative/Correspondence #2" (PDF). The FDA Center for Drug Evaluation and Research. 2003. Retrieved 2008-05-18.
- ↑ FDA news
- ↑ "Summary Basis of Decision (SBD): Cymbalta". Health Canada. 2008-05-05.
- ↑ Steyer R (2006-02-15). "Lilly Won't Pursue Yentreve for U.S.". TheStreet.com. Retrieved 2008-05-18.
- ↑ Lenzer J (2005). "FDA warns that antidepressants may increase suicidality in adults". BMJ. 331 (7508): 70. doi:10.1136/bmj.331.7508.70-b. PMC 558648. PMID 16002878.
- ↑ "FDA approves antidepressant Cymbalta (duloxetine HCl) for treatment of generalized anxiety disorder". News-Medical. February 26, 2007. Retrieved 25 December 2013.
- ↑ Staton, Tracy (July 9, 2012). "Lilly could net $1.5B-plus from Cymbalta extension". FiercePharma. Retrieved 25 December 2013.
- ↑ Palmer, Eric (April 11, 2013). "Eli Lilly to lay off hundreds in sales as Cymbalta nears edge of patent cliff". FiercePharma. Retrieved 25 December 2013.
- ↑ Anson, Pat (December 12, 2013). "Generic Cheaper Versions of Cymbalta Approved". National Pain Report. Retrieved January 2, 2014.
External links
- Eli Lilly Cymbalta Prescribing Guide
- U.S. National Library of Medicine: Drug Information Portal - Duloxetine

subset: commoncrawl


text:
This vehicle has now been sold. Feel free to browse our great selection of currently available stock.
- Vehicle: 2019 [SOLD] Picanto
- Series: JA
- Badge: S
- Colour: Clear white
- Body: Hatchback
- Engine: 1.25 litre, 0-cylinder MPI Aspirated
- Fuel Type: Petrol
- Transmission: 4-speed Automatic
- Doors: 5-door
- Seats: 5
- Trim: BLACK
- Registration: 515892
- Stock Number: 515892
- Compliance Date: 08/2018
Highlighted Features
- 14" Steel Wheels
- 7" full colour LCD touch screen
- Android Auto�
- Apple CarPlay�
- Rear view camera with in-audio screen display and parking guidelines
- Seats - Cloth
Standard Factory Specifications
- Engine Power: Max. power: 62kW @ 6000rpm
- Fuel economy (combined): 5.8 L/100km
- Fuel economy (extra urban): 4.6 L/100km
- Fuel economy (urban): 7.9 L/100km
- Torque: Max. torque: 122Nm @ 4000rpm
Factory Standard Features
- 60/40 Split-fold Rear Seats
- Air Condtioning - Manual
- Airbags - Driver and front passenger SRS
- Airbags - Front side and curtain SRS
- Anti-lock Braking System (ABS)
- Anti-theft immobiliser
- Audio System - 4 speakers
- Audio System - AUX/USB input
- Audio System - MP3 CD Player
- Bluetooth® connectivity
- Brake Assist
- Burglar alarm with security indicator
- Electronic Brakeforce Distribution (EBD)
- Emergency Stop Signal (ESS)
- Halogen Daytime Running Lights
- Headlights - Dusk sensing automatic
- Hill-start Assist Control (HAC)
- Impact sensing door unlocking
- Multi-Function Trip Computer
- Power Mirrors
- Power Windows
- Rear parking sensors
- Rear spoiler
- Remote central locking with keyless entry and tailgate release
- Steering Wheel - Audio Control
- Steering Wheel - Cruise Controls
- Traction Control System (TCS)
- Vehicle Stability Management (VSM)
- iPod connectivity
* Financed over 5 years on a Chattel Mortgage with a 30% residual value. Repayment subject to approval, fees & charges payable. To approved applicants only. Please contact us for details, including full terms & conditions.
Disclaimer: Please confirm price, specifications and features with the Dealership. The Dealer's actual prices may vary from the published price for a number of reasons, including additional charges applicable under the laws in your state. Contact the dealer to confirm the final drive away price that will apply to your purchase. The Dealer and its providers of data have been diligent in providing accurate and complete information. However, the Dealer and its providers do not warrant the accuracy or completeness of the data. Please contact the dealer to confirm the details of this vehicle. Use of this website indicates your acceptance of our Terms & Conditions.


text:
The fitness industry and health professionals are always coming up with the best ways to lose weight, get a flat stomach and build muscle. We all know that for many years cardio has been at the top of the list in helping people burn fat and lose those excess pounds. For the past few years, most fitness professionals recommended performing long periods of less intense forms of cardio, such as walking on the treadmill for an hour or so. However, after years and years of performing these types of exercises, many people were not getting the results that they wanted, which lead to the fitness industry reevaluating the best way to lose weight.
Fat burning potential
For the last couple of years, health professionals have been telling us to perform long periods of low intensity cardio to lose weight. They based this theory on the idea that since we burn primarily fat while doing low intensity exercise and end up burning mostly carbs while performing high intensity exercises, we would lose more weight with the longer less intense form of cardio. However, when people were not achieving the results that they wanted, the professionals decided to take another look. What they found was that high intensity cardio was actually more effective at burning fat than longer less intense periods of cardio. They discovered that if you are not using carbs for energy then your fat cells are not able to take advantage of the energy pathways that carbs use, which means that you are unable to burn them. Therefore, you need to do some sort of high intensity exercise to allow your body the opportunity to burn fat.
Which is better
Most of us would believe that if high intensity cardio burns more fat, then that is all we should be doing. However, in your quest to lose weight and become healthier, it may not as simple as choosing one form of exercise over the other. There are many different benefits associated with each type of exercise, and you should make room for both types in your fitness routine in order to get the optimal results. Long periods of less intense cardio has been shown to reduce your triglyceride levels and increase your good cholesterol levels. It has also been shown to help improve the effectiveness of insulin to do its job and helps to eliminate glucose from your blood. So, while performing long periods of low intensity cardio may not help you lose the weight you want, it can benefit you in the long run.
It may not be as easy as deciding on one type of exercise over the other. You should never limit your fitness routines this way. There should always be room for multiple types of exercises in your fitness routine. Do not be afraid to add some variety to your workout to get the best results. By doing different types of exercises you can easily spice up your fitness routine and stave off boredom, which can have you looking forward to your next workout.
– See more at: http://www.9round.com/blog/which-is-better-long-low-intensity-cardio-routines-or-high-intensity-interval-training/


text:
A bit more than three weeks ago we presented our Standard format project. After having read your comments we changed the way to implement it. No need to go back over the previous version of this project (you can read the 700 and more comments if you wish), I'm going to talk about the final version.
The goal is still the same : offer a scalable and restrictive format.
Today, we have to many playable characters in each clan. New players are lost with all these options while paradoxically, old players own the best characters but always play with the same ones. With the Standard format, we want to offer to the new and old players a more restrictive environment if they wish, with less options in each clan but more often renewed.
What will we do?
1/ Create a list of characters called "Standard" which will be reset half-yearly. In this list you'll find all characters (and LD too) released within the three last years before the update, Leaders, starter deck characters and characters released after the update. You'll find 13 to 16 characters in each clan. New clan will keep all their characters.
2/ We will create a new deck format:
Standard format: Standard characters only, 40 stars max., no double.
3/ T1 and T2 will be renamed in Extended and Extended 25.
Extended format: all characters are allowed, 40 stars max. no double, equivalent to the current T2.
Extended 25 format: Extended characters, 25 stars max., no double, equivalent to the current T1.
4/ Several changes will be made on the DT.
- The timer will be significantly reduced for all DT matches. From the first match you'll have the same timer as the one you have now above 100 points.
- We will create a list of penalized characters in DT which will be independent from the list of ELO banned characters. The rule will probably remain the same: -2 points for each penalized character un your 4 characters team. We might change the penalty in the future if necessary.
- T1 and T2 room will be merged in one single room Extended Fights. To allow you to play with 15 to 40 stars decks, the battle system will make you face opponents with similar decks. The DTs will always be in this room.
- There will always be a DT every other our but alternately with the two rooms, Extended and Standard. it means there will be a DT one hour out of 4 in the Extended room and the same in the Standard room.
- We will randomly give a collector to players ranked in the top 150 in DTs. We didn't decide the exact number of collectors yet nor the rules of the draw but we're thinking about 5 collectors a day.
I insist on the fact that with the system of matches against similar decks (which already exists on T1 and T2 rooms) you'll be able to build competitive decks with a small number of stars as you'll always face similar decks. Le big difference is that 25 stars decks will face slightly bigger decks and 26 stars decks will face slightly smaller ones. It doesn't happen now because of the rooms limits which don't match with the way DT decks are built.
5/ We will create two new battle rooms.
- Deathmatch Standard: just like the current DM T2 but with Standard decks.
- Survivor Standard: just like the current Survivor T2 but with Standard decks.
6/ We will also make some minor changes as:
- new packs in the shop with Standard characters only.
- sorting options in the collection to only see Standard characters.
- changes in the theme decks (we are still thinking about it).
- minor changes in the visuals of cards to make Standard characters easier to recognize.
You may notice that ELO won't change at all, the same for DM or Survivor rooms. Of course the Fight Club and the Warehouse won't change either.
About the deadline, with all these changes we cannot be sure it will be released on March. We are working on this project and we want to release it quickly but I can't give a date but it should be implemented before this summer.
You can post comments or send emails here: email@example.com
Thank you and have fun!
Lu Bu Imperator Limit Break Saturday 03/03/2012, 20:45
@Andyman maybe a survey/questionnaire?
@Meelosh I personally agree with the timer reduction. Faster is better - if you don't want to win the DT then just play fast to 100pts~ and stop playing.
DivaDestiny Titan The Infinite Shoeblack Saturday 03/03/2012, 22:09
@Meelosh- I think your style of game play is probably more suited to a format like elo where the more strategic player will win.
DTs are won by the player who can KO the fastest. The shorter time limit would take away some of the element of chance and make it more a contest of skill.
generalguy64 Hero Sunday 04/03/2012, 00:25
Changing the packs' prices could hurt a lot of "casual players" (people who don't really care about tournaments.) Instead of fully changing packs to standard cards only and raising the price, could you offer separate packs for standard cards?
-DustStorm- Imperator Open Casket Sunday 04/03/2012, 01:43
@generalguy thats what they're doing...
Travis {TAB} Imperator Monday 05/03/2012, 14:08
Whats the point of Standard if it doesnt replace ELO
I thought that was the point
Skittish Colossus Open Casket Monday 05/03/2012, 15:27
Travis hit the nail on the head for me, Whats the point of Standard if it doesnt replace ELO?
Lafoote Titan Hip Hop Messiahz Monday 05/03/2012, 16:09
Still have an overwhelming hatetred of all the extended being in one room. If i build a 25 star deck, I have no interest in playing against people with 27 or 28 stars.
Lu Bu Imperator Limit Break Monday 05/03/2012, 22:58
Because ELO apparently doesn't need to change. And to be honest, DT does.
SleepDisciple Senior Monday 05/03/2012, 23:23
This is so much better... elo was the problem... and now the market won't crash every second friday


text:
In August 1950, it was Bernard D'Andrea's turn to tackle the "graphic art" assignment for Woman's Home Companion magazine.
He turned in this eye-catching experiment in high contrast illustrative design which is so forward thinking, one could almost imagine Patrick Nagel creating it in the 1980's - at the same time it evokes the era of the Gibson Girl.
D'Andrea remained true to the principles of the New School of illustration: focus on the head and hands, eliminate background environment, use only props relevant to the story, large areas of flat colour that emphasize strong design.
Below is another great example of those principles as rendered by D'Andrea - but this time in his more typical painting technique. It was his WHC contribution from two months earlier. Throughout this run of issues I have, spanning 1948 to 1952, Bernard D'Andrea regularly contributed story illustrations to the magazine. The piece above is the only one I've seen where he attempted this graphic, high contrast approach. In fact, I don't think I've seen another D'Andrea in that style in any 1950's publications.
You may think I'm making too big a deal out of something trivial - but in the context of the times and within the narrow confines of the women's magazine story illustration niche that top piece is genuinely radical!
What inspired Bernard D'Andrea's foray into graphic experimentation? I welcome your thoughts on the matter.
These images can be found at full size in my Bernard D'Andrea Flickr set.
Celebrating illustration, design, cartoon and comic art of the mid-20th century.
Tuesday, September 25, 2007
Bernard D'Andrea - Graphic Artist
3 comments:
I think he was trying to start a new style of illustration to refresh the magazines a new wave or something like that.ReplyDelete
- Anonymous1:30 AM
This is a great site! Illustration art rocks!ReplyDelete
Speaking of Patrick Nagel's work, please come visit a new forum set up by some of his fans:
Subscribe to: Post Comments (Atom)


text:
Brendon S needed a new web page design and created a contest on 99designs.
A winner was selected from 76 designs submitted by 16 freelance designers.
http://www.sanctuarybeach.com.au requires a complete redesign of their website. The design needs to fit with the Word Press Theme Thesis.
Sanctuary Beach Resort
Please create a website design that can be applied to a WordPress Theme called Thesis. An example of the default theme is http://www.snuggs.com/ and two customised versions of this same theme are http://www.chisel-fitness.com.au/wp/ http://www.pilagroup.com.au/
We would like to develop Sanctuary Beach with only 2 columns, so the sidebar will only contain one column.
Please develop a design that is modern and clean. The client likes the colours yellow and blue. Please DO NOT USE THE GREEN in the current design.
The property is 'absolute beachfront' with 'sand on your doorstep' so please try to emphasise this within the design.
The property is located in Currumbin on the Gold Coast in Queensland. Tourism is a huge industry on the Gold Coast so a smart and professional design is what we are looking for.
Please do not use the logo found on the current site. Please come up with a text logo for this new design using the words 'Sanctuary Beach Resort'.
The client would like the design to feature one or more of the aerial images. Please find some images to use within the design at the following locations.
- Layered PSD file
- A design that can work as a wordpress theme (Thesis)
- Prize payment via paypal only
- Dark text on a light background (easier to read)
- No animation
- No flash
- Avoid a 'busy' design


text:
The Other Guys
Now Available
About The Other Guys
Misfit NYPD detectives Gamble and Hoitz (Will Ferrell and Mark Wahlberg) are sentenced to life behind the desk. They hate each other and the monotony of their meaningless jobs, as they're forced to live in the shadow of the two biggest and most badass cops on the force (Samuel L. Jackson and Dwayne Johnson). But when those guys go down for the count, opportunity knocks for Gamble and Hoitz. Stumbling onto what could be one of the biggest crimes in years, can The Other Guys step up their game to solve the case without killing each other and destroying NYC in the process? From the director of Step Brothers and Talladega Nights: The Ballad of Ricky Bobby.
Josh Church, Jessica Elbaum
Adam McKay, Chris Henchy
Executive Producer
David Householter, Chris Henchy, Kevin Messick
Will Ferrell, Adam McKay, Patrick Crowley, Jimmy Miller
Adam McKay
Steve Coogan, Will Ferrell, Samuel L. Jackson, Michael Keaton, Mark Wahlberg, Eva Mendes, Dwayne Johnson, Ray Stevenson


text:
Roy Bennett, a top figure in Zimbabwe's Movement for Democratic Change (MDC), was acquitted Monday of terrorism charges and of an alleged plot to overthrow the government of Zimbabwe President Robert Mugabe.
Mr. Bennett, a white commercial farmer who faced possible execution if convicted, had offered this past weekend to step down from his appointment as MDC's choice as deputy minister for agriculture. He told The Guardian that he would not stand in the way of the "restoration and reconstruction" of Zimbabwe.
"A single post should not stop that process moving forward," he was quoted saying. "So if it meant [that I should] step aside completely and not be involved, and that would move the process forward towards a fresh election and towards democracy, I would be the first person to endorse that."
Bennett's status has long been a stumbling block for the fragile coalition government of Prime Minister Morgan Tsvangirai and President Robert Mugabe. Since the September 2008 power-sharing agreement, following shady April 2008 elections, Mr. Mugabe has refused to swear in Bennett citing Bennett's pending criminal case. But analysts also say that Bennett's selection for the agriculture ministry was sensitive because of the danger of him reversing Mugabe's land-reform policies and the often violent seizure of white-owned farms by Mugabe's supporters.
Could Bennett's acquittal and his offer to step aside be part of a face-saving deal between Mugabe and Tsvangirai to move forward?
That's unlikely, says Judy Smith-Hohn, a Zimbabwe analyst at the Institute for Security Studies in Pretoria (a city also known as Tshwane).
"I think Roy Bennett's offer to step aside is a major step, a real sign of willingness on the part of MDC to get this process moving again," says Ms. Smith-Hohn. "Whether ZANU-PF [Mugabe's party] is going to recognize that step, or continue to focus on the issue of sanctions, it is too early to say."
Progress depends on AU, SADC
The only way Zimbabwe will resolve the current political impasse, she says, is if it is forced to do so by other African states, under the umbrellas of the African Union and the Southern African Development Community. "The only time ZANU-PF has compromised is when the [African Union] and [Southern African Development Community] had the same message, that you need to form a government of national unity," says Smith-Hohn.
The AU and SADC need to send Mugabe the unified message that he must cooperate with his coalition partners if he wants sanctions lifted, says Smith-Hohn.
SADC's current mediation process, led by South African President Jacob Zuma, seems to have stalled, but it has recently been joined by Congolese President Joseph Kabila, a close friend and supporter of Mugabe.
Whether this new energy by SADC will give a helpful shove to the mediation remains to be seen, of course, and Smith-Hohn warns that SADC remains deeply fragmented over whether to start speaking tough to Mugabe.
"[Mr. Kabila] is a longtime associate of Robert Mugabe, and he trained in Zimbabwe and has personal ties with Mugabe, so whether his involvement in the mediation is helpful or not is hard to say," says Smith-Hohn. But removing Bennett as a negotiating point could help move the process forward, she says. "What is ZANU-PF going to do in return? That, we will see in the next few hours or days."
Will Bennett stay or go?
There's also some question as to whether Bennett really will agree to step aside. He appeared to contradict his earlier message this weekend on Monday by saying: "Mugabe has to swear me in now. My party has made it very clear that they expect nothing less."
MDC spokesman Nelson Chamisa affirmed this Monday, indicating that the MDC wants to test what Mugabe will do before deciding how prominent Bennett's future role should be.
"We have been vindicated. This was not prosecution but persecution," Mr. Chamisa said. "We are expecting that the natural thing will happen, that we will wake up with Bennett as deputy agriculture minister."


text:
Graduate Coordinator: Nancy Mirabal
ProfessorsAlmaguer, Begonia, Chew, Cordova, Cuellar, Diaz, Dong, Head, Hom, Kobashigawa, Nobles, Obenga, Rivera, Tsuruta, T'Shaka, Yansane, Yoo
Associate ProfessorsAbdulhadi, Barker, Carrillo, Garcia, Ginwright, Gonzales, Jeung, Jolivette, Le, Mirabal, Murguia, Nelson, Pelaud, Richards, Sueyoshi, Tintiangco-Cubales
Assistant ProfessorsAkom, Bakrania, Collins, Dariotis, Duncan-Andrade, Esquibel, Ferreira, Fischer, McDougal, Reyes, Soe, Ueunten, Washington
M.A. in Ethnic Studies
The Master of Arts in Ethnic Studies is collectively administered by the Chairs' Council of the College of Ethnic Studies. It is designed to increase students' knowledge and understanding of the experiences of people of color. The program provides training in techniques for the analysis of historical and contemporary social problems related to these experiences, and the curriculum develops students' capacity to structurally assess, plan, and evaluate social policies aimed at the resolution of these problems. Although the focus remains primarily on the condition of Asian Americans, African Americans, Latinos, and American Indians, the program is increasingly concerned with mixed race studies, human sexuality studies, diaspora studies, postcolonial criticism, theories of racial formation, the experiences of other communities of color, and theory/practice of resistance and social movements.
The program is designed to prepare individuals for advanced graduate work leading to the doctorate or professional roles in teaching, research, and administration within both the public and private sectors. The theoretical and conceptual tools of several disciplines are critically utilized and analyzed. The program applies cutting edge analyses, such as cultural studies, postcolonial, feminist, and queer perspectives, to instruction, research, and community involvement. Both scholarly and activist engagements with the surrounding San Francisco Bay Area communities of color are encouraged and expected.
The Master of Arts in Ethnic Studies is designed to be a versatile degreeone that is inclusive rather than exclusive of employment opportunities. These possibilities range from ethnic oriented teaching and research to community and multicultural resource development to practical application in the business and technical fields. Program graduates are also eligible to apply for teaching positions at the California community colleges in ethnic studies and related fields.
Graduates with this increasingly sought after expertise have begun establishing an impressive employment history. Approximately 25 percent of graduates go directly into teaching at community colleges or four-year institutions. An additional 25 percent enter various professional fields, including K-12 teaching, youth-related social programs, and community advocacy research.
Approximately 50 percent of the graduates proceed on to doctoral studies in a wide range of subject areas, including ethnic studies, anthropology, sociology, American studies, health education, multicultural education, communication studies, and African American studies. Although the graduate program only has been in existence since 1988, alumni of the M.A. in Ethnic Studies have gone on to Ph.D. programs at a broad array of prestigious institutions. These include various University of California campuses, Temple University, Stanford, Yale, Purdue, the University of Michigan, the University of Massachusetts, the University of Hawaii, and Harvard University.
A student must meet the general university requirements, along with the College of Ethnic Studies requirements:
Applicants interested in the graduate program in ethnic studies must file a California State University graduate application with the university graduate admissions office. In addition, a separate program application form must be completed and returned to the Ethnic Studies graduate program office. Applicants must submit to the graduate coordinator of the College of Ethnic Studies (on behalf of the College of Ethnic Studies Graduate Admissions Committee) the following information:
Applications are accepted for fall semester admissions only. The application deadline is February 1. Program information and applications are available at the College of Ethnic Studies web site: www.sfsu.edu/~ethnicst.
Level One: this first level must be met through satisfactorily meeting the writing requirements in ETHS 710. Level Two: in addition, students must indicate a method of demonstrating their further competency in English at the time of filing the Graduate Approved Program. The latter assessment of competence is evidenced by the writing of a field study or a master's thesis.
In addition to fulfilling all the university requirements, the student must file a Graduate Approved Program after having completed 24 units, but no more than 24 units, of work applicable to the M.A. in Ethnic Studies, with a grade point average of 3.0 or better. Before filing the Graduate Approved Program, the student must demonstrate proficiency in written English and complete any other program pre-candidacy requirements. The proposed course of study when approved by the dean of Graduate Studies means the student has been advanced to candidacy.
Courses are 3 units unless otherwise indicated. On-line course descriptions are available.
|Theories and Concepts in Ethnic Studies
|Seminar: Contemporary Discourse in Asian American Studies
|Seminar in Africana Studies
|Seminar in American Indian Studies
|Seminar in Raza Studies
|Research Methods in Ethnic Studies
|Community Practicum
Graduate Projects in the Teaching of Ethnic Studies
|Advanced Research Seminar in Ethnic Studies
|Area Emphasison advisement
|Field Study
|Minimum total
Students are required to focus on an area of emphasis in Africana Studies, Raza Studies, Asian American Studies, American Indian Studies. In addition the program offers students the opportunity to develop expertise in Arab Muslim Ethnicities and Diaspora studies, and critical race and resistance studies employing comparative methodology. Courses selected to fulfill the emphasis will provide a student with the subject matter foundation to complete the culminating research project field study or thesis. Upon advisement, upper division/graduate course work in the College of Ethnic Studies and other departments on campus may be used.
1600 Holloway Avenue, San Francisco, CA 94132 (415) 338-1111
Last modified July 06, 2012 by email@example.com


text:
Product Details
Basic Info
Model NO.: DB18040#
Technics: Embroidered
Color Production: Dyed
Lace Craft: Embroidery Lace
Applications: Clothing
Product: Lace
Color: Customized
Name: Embroidered Lace
Quality: A Grade
Delivery Time: After Payment 1-2 Working Days
Trademark: Diligent
Specification: 125CM
HS Code: 5810920000
Material: Polyester
Style: Trimming
Pattern: Stripes
Manual Process: Around
Categories: Embroidery Lace
Keyword: New Lace Designs
Samples: Free
Package: Roll/Plastic Bag/Carton
Feature: Eco-Friendly
OEM: Yes
Transport Package: Poly bag/Carton
Origin: China
Product Description
New Fashion Design French Lace
1. Be Satisfied: satisfied services, reasonable prices, top fashion designs.
2. Be Reliable: Check the quality as the product was done.
3. OEM Service: Can be customized as per sample or pictures.
4. Promptly reply you within 24 hours.
5. Fast delivery time.
6. 100% quality guarantee.
|100% polyster
many different color
Fabric type
swiss voile lace
10pcs for ready goods
Payment terms
Western union, moneygram,T/T,L/C,Cash
For best wholesale price,pls feel free to email or call us !!
By DHL/UPS/FEDEX/TNT,by air,by sea
1-5working days
Hot market
Suitable for Africa ,Europe and the Americas Market
Sample charge
1. Samples charge:available sample free of charge . Sampling time: 1days.
2. Samples charge:Re-design sample free of charge .Sampling time: 1-2day.
1. Low MOQ: It can meet your promotional business very well.
2. Good Service: We treat clients as friend.
3. Good Quality: We have strict quality control system .Good reputation in the market.
4. Fast & Cheap Delivery: We have big discount from forwarder.
Why choose us
1. We are a professional company in this line.
2. We have very strong financial system and enjoy good reputation.
3. Customer's design and logo are available.
4. Small order and massive production are available
Basis Services
1.Free sample& Free sample analysis
2.24Hours online& Quick response
3.Pick up to our factory come and back
4.Tens of thousands of designs for you to choose from
5.All production in stock
6.Quality inspection
Customized Services
1.We have Product Development Team to develop the new products to meet your need
2.We have design development Team to develop the new designs, customized designs are welcomed
3.For the packing and loading, we also accept customized requirement.
After-sale Services
1.When clients receive the goods, if any quality problems, pls contact us freely.
2.We will have a disscuss about it to make you satisfied
3.And we never let it happen next time.


text:
Isles' Vanek embracing the outdoor game experienceby Adam Kimelman
Thomas Vanek learned very quickly one of the benefits to being traded to the New York Islanders.
It wasn't long after the Oct. 27 trade that sent him from the Buffalo Sabres to New York that his phone started ringing, with ticket requests for the 2014 Coors Light Stadium Series game between the Islanders and New York Rangers at Yankee Stadium on Jan. 29, 2014.
"That was one of the first things when I got traded here," Vanek told NHL.com. "Days after I'm getting texts out of nowhere, you guys are playing outdoors. My ticket list is growing."
The Yankee Stadium game will mark the second time Vanek has taken part in an NHL outdoor game. He was with the Sabres on Jan. 1, 2008 for the inaugural NHL Winter Classic at Ralph Wilson Stadium in Buffalo.
Tickets to the two games at Yankee Stadium (Rangers vs. Devils, Jan. 26, 12:30 p.m. ET and Rangers vs. Islanders, Jan. 29, 7:30 p.m. ET) are on sale now. BUY TICKETS ›
Sign up to receive more info: www.NHL.com/2014NewYork
The day featured more than 70,000 fans packed into the home of the Buffalo Bills, and the game had the raucous atmosphere of an NFL Sunday.
"I think we pulled in at nine in the morning and people are tailgating and having fun," Vanek said. "You knew the day was here but just walking out for warmups, game time with the fireworks and seeing the people go nuts, that was fun."
Vanek said what he remembers most from the game is the sea of faces as he and his teammates walked out toward the ice.
"Walking out of the tunnel and seeing the people and stuff, the atmosphere, it was something you picture, but until you go through it, that was the wow factor for me," he said.
With his outdoor game experience, Vanek could serve as a touchstone for teammates going through it for the first time. While Vanek said he'd answer whatever questions he could, he said the only real way to handle it was just to experience it.
"You can't tell guys about the game or whatever," he said. "They'll figure it out. As far as the experience, just take it in and make sure you're ready.
"It's just a great memory. Just soak the day in because in Buffalo it was a long day, but looking back at it, it was awesome. It's something you can always look back at, tell your buddies 20 years from now or let your kids know about it. Just a special day. Obviously it's still important to get the two points, but soak in everything around it."
Vanek said he's looking forward to going outside again, especially at Yankee Stadium. While he was born in Austria, Vanek has been in the United States long enough to know what Yankee Stadium means in the annals of American sports history, and just how much playing a hockey game there means.
"I think it's different," he said. "For Buffalo, they live for the Bills and Sabres. For that city to combine those two sports in one venue was pretty special. Now you're talking about Yankee Stadium, New York. That adds another element. I'm looking forward to it."


text:
It's been over a year since human rights lawyer Gao Zhisheng was detained in the remote Shaya Prison in Xinjiang Province, and only recently was he allowed to meet his family for the second time. They had not been permitted to visit since March 2012.
Gao, sometimes calling "China's conscience," was arrested, harassed and tortured from 2005 onwards after defending persecuted practitioners of Falun Gong, a traditional spiritual discipline, and other groups targeted by the regime.
Gao's eldest brother told Sound of Hope (SOH) radio on Jan. 18 that he had been trying to visit his detained brother for a long time, and only after he threatened to appeal in Beijing did the authorities allow his family to visit Gao in prison.
Gao's wife, Geng He, who currently resides in the United States with their children, maintained that Chinese communist authorities are afraid her family would expose her husband's situation to the international community if they visited him.
His younger brother and father-in-law traveled far to see him, but were only granted a half-hour visit under strict monitoring and control.
During the short meeting, Gao could only ask about the family's wellbeing. His only words for his wife were to raise the children well and don't worry too much about him.
Geng told Radio Free Asia (RFA) that prior to their visit, the prison had forbidden them to ask any questions about Gao's treatment; violating this rule would lead to immediate termination of the visit, she said.
During the meeting, Gao's brother asked whether he could read newspapers or watch television but was abruptly interrupted before Gao was able to speak; a guard said that Gao wasn't allowed.
Geng told RFA that the family made great efforts to get a chance to see him. The journey across the remote region of Xinjiang to the prison is harsh and takes around 10 days. The most important aspect of the encounter was to verify that Gao is still alive.
Sound of Hope Radio interviewed several well-known Chinese human rights activists after the short prison meeting.
Beijing human rights activist Hu Jia said that over the past eight years, Gao Zhisheng has constantly suffered brutal torture by the Chinese Communist authorities.
Hu said Gao is locked up in a place referred to by the Uyghur locals as a "terrorist prison."
"The evil of the Chinese Communist Party (CCP) is fully implemented by the propaganda system and the politics and law system. Regardless of whether they are the Internet and media censors, or the political and local police that block petitioners, evil is being implemented through these various individuals. So when we are faced with these evil people, we must understand, fundamentally, it is the evil of the system, the evil of the CCP," Hu said.
According to human rights lawyer Tang Jingling from Guangzhou, who is familiar with the CCP's persecution of the prisoners of conscience, Gao has very likely been suffering from "strict control" and torture.
Tang added that "strict control" as implemented by guards is "very cruel": the victim is forbidden to speak to anyone, or is often in solitary confinement in a small cell, or sometimes in a cage or small space, where they cannot stand up, or sit or lie down. Over time it is agonizing, Tang said.
Editor's Note: When Chongqing's former top cop, Wang Lijun, fled for his life to the U.S. Consulate in Chengdu on Feb. 6, he set in motion a political storm that has not subsided. The battle behind the scenes turns on what stance officials take toward the persecution of Falun Gong. The faction with bloody hands—the officials former CCP head Jiang Zemin promoted in order to carry out the persecution—is seeking to avoid accountability for their crimes and to continue the campaign. Other officials are refusing to participate in the persecution any longer. Events present a clear choice to the officials and citizens of China, as well as people around the world: either support or oppose the persecution of Falun Gong. History will record the choice each person makes.
Read the original Chinese article.
The Epoch Times publishes in 35 countries and in 21 languages. Subscribe to our e-newsletter.
Click www.ept.ms/ccp-crisis to read about the most recent developments in the ongoing crisis within the Chinese communist regime. In this special topic, we provide readers with the necessary context to understand the situation. Get the RSS feed. Who are the Major Players?


text:
Mention Atlanta and images of uncontrolled urban sprawl and descriptions of hellish commutes inevitably arise. For years the city, the ninth largest in the United States, served as the poster child for unchecked growth. In fact, the metro area is so spread out today that at 8,400 square miles it rivals the entire state of Massachusetts.
But Atlanta's civic and business leaders have made a sharp turn in recent years to prevent further sprawl and instead refocus attention on in-fill projects. As the city continues to add residents — in the past seven-plus years, the population of the inner city alone has grown another 11.5 percent to 464,200, according to the Atlanta Regional Commission — public and private forces have teamed up to turn the Big Peach into a mixed-use mecca as a host of live/work/play projects crop up in and around Atlanta.
The current growth initiative began in the early 2000s with Atlantic Station, a joint venture redevelopment effort between AIG Global Real Estate Investment Corp. and Atlanta-based Jacoby Development, Inc. The $2 billion project, touted as one of the largest brownfield redevelopments in the country at 138 acres, turned the 100-year-old Atlantic Steel Mill near downtown Atlanta into a model mixed-use community, complete with 6 million square feet of Class-A office space, 2 million square feet of retail and entertainment venues, 5,000 residences, 1,000 hotel rooms and 11 acres of public parks.
The verdict on the Atlantic Station is still out — the property attracts healthy, but hardly spectacular, foot traffic, according to Brian Lefkoff, senior vice president with Atlanta-based brokerage firm Colliers Spectrum Cauble. But the developers set the tone. All around Atlanta, construction crews are working on mixed-use developments, with the city itself planning to integrate high-priced condominiums and office space along the main thoroughfare of Peachtree Street into an urban retail environment on par with Madison Avenue in New York and the Magnificent Mile in Chicago.
Last year, for example, Atlanta-based developer Sembler Co. completed the 452,000-square-foot Perimeter Place, which in addition to its retail component, features 550 residential units. In the fall of 2008, the firm plans to complete the redevelopment of the Prado, a 345,000-square-foot shopping center, into a mixed-use property, combining retail, restaurant and office space. And in the spring of 2009, Sembler will deliver Brookhaven Village, a project located on Peachtree Road, which will contain 600,000 square feet of big-box retail and restaurants and 1,500 residential units.
Meanwhile, another local developer, Ben Carter Properties, recently started construction on the Streets of Buckhead, in Atlanta's affluent Buckhead District. The project, which will contain a total of 800,000 square feet of commercial space, will feature 500,000 square feet of luxury retail, 300,000 square feet of Class-A office space and 1,000 residences when it opens in the fall of 2009.
Lured by the area's high income levels and traffic counts — Ben Carter estimates that 50,000 people pass through Peachtree Road every day — such upscale names as Hermès, Etro and Bottega Veneta are already committed to the project.
"We are seeing a lot of mixed-use here," says Jackie Wammock, senior vice president with Atlanta-based development firm Ronus Properties. Wammock believes that Atlanta's high land prices play a role in developers' decisions to invest in vertical, mixed-use projects rather than traditional shopping centers and malls. In some areas of Atlanta, land zoned for retail development currently sells for $1,000 per square foot, according to a report from NAI Brannen Goddard, an Atlanta-based real estate brokerage firm.
Creating a masterpiece
The true test of Atlanta's ability to turn itself from a fuel-addled sprawl capital into a pedestrian-oriented city will be the public/private project unfolding in the midst of the city's famous Peachtree Street. Earlier this spring, the Peachtree Corridor Task Force, chaired by Cousins Properties' chairman and CEO Tom Bell, unveiled the final plans for the creation of the Midtown Mile, a 14-block-long stretch of Peachtree Street the task force would like to turn into a cosmopolitan shopping district.
The task force estimates that the area currently contains more than 36 percent of Atlanta's retail space and 24 percent of its office space, housing 220,000 workers, or 50 percent, of Atlanta's jobs. Meanwhile, the number of residents in the neighborhood doubled to 30,000 since 2000 and will grow another 73 percent by 2016, to 52,000 people. By spearheading the creation of accessible, street-level retail on the ground floors of office and residential buildings, the task force hopes to create a pedestrian enclave within the city's central district, while simultaneously connecting the neighborhoods of Buckhead, Midtown, Downtown and Ft. McPherson.
In order to complete the $1 billion project, Atlanta plans to create a special tax district and use city-issued bonds, along with federal and state grants, to fund streetscape improvements, construction of supporting utility infrastructure and land acquisition. It already partnered with 12 private enterprises, including Cousins Properties, Jamestown Properties, Selig Enterprises and Tivoli Properties, Inc., among others, to participate in the creation of Midtown Mile. When completed, the project will contain one million square feet of retail. Currently, the area houses 367,000 square feet of retail space.
Selig Enterprises, in partnership with the Daniel Corp. and the Canyon-Johnson Urban Fund, already started work on the largest component of Midtown Mile — 12th & Midtown — a three-block-long, 2.5-million-square-foot mixed-use development slated to contain 1.2 million square feet of office space, 150,000 square feet of multilevel retail, 600 residences and 500 hotel rooms.
"There has been a resurgence of population moving back into the city and the development on the multifamily side is driving retail demand," says Shirley Gouffon, senior vice president with Selig. "The Midtown Mile will help redevelop downtown Atlanta to accommodate flagship retail from all over the world."
Selig plans to deliver the first phase of 12th & Midtown, which will combine 443 residences with 50,000 square feet of retail space, in September 2008. The second phase, combining a 725,000-square-foot office tower, 60,000 square feet of retail and a 400-room hotel, will come on-line in September 2009. Several big-name tenants already signed leases for the space at 12th & Midtown to house their first Atlanta locations, according to Gouffon, but she declined to reveal their names.
Meanwhile, this August, the Peachtree Corridor Task Force revealed plans for a $1 billion streetcar project, which the task force hopes will become the centerpiece of the Midtown Mile redevelopment. Modeled on the streetcar system in Portland, Ore., which received a financial boost from both city and state, Atlanta's streetcar system would feature 90 stops along the Peachtree Street corridor. The Atlanta City Council will deliberate on the project this fall.
What's in store
The big question now is whether, with all that new space in the pipeline, the retail demand in Atlanta will continue to hold strong. Atlanta still ranks among the top 10 cities in the nation for retail sales at $74 billion annually and its real estate fundamentals remain solid, according to the national brokerage firm Marcus & Millichap Real Estate Investment Services. But the vacancy rate for retail properties in the Atlanta metro area will rise 20 basis points this year, to 8.2 percent, while its retail sales growth will slow to 6 percent, Marcus & Millichap researchers estimate. Last year, Atlanta posted retail sales growth of 8.5 percent.
Meanwhile, Atlanta's rental rates will likely remain at their current level, says Lefkoff. Retail rents in the city now average $14.48 per square foot, according to Colliers Spectrum Cauble, and the developers with projects now in construction had better prepare themselves for a tenant's market.
"The majority of national retailers that I have seen are not going above a $30 mark to do a deal here unless it's in the heart of Buckhead or in another area that is so dense it's virtually impossible to get into," says Lefkoff. "And even then it would be rare to see them go above $35 per square foot."
The condo market in Atlanta is also entering a down cycle, according to Wammock, a development that will likely affect some of the mixed-use projects currently in the pipeline. Sales velocity in the condo market declined 23 percent since 2006, according to Marcus & Millichap.
"I think the larger retail and mixed-use projects that are already under way and have tenants committed to them will continue to move forward," says Wammock. "But we'll probably see some slippage on smaller unanchored centers."
When it comes to the Midtown Mile, the development will likely do wonders for Atlanta's new image by putting retail on the street level, but Lefkoff thinks it might be a while before the city's residents get used to thinking of Atlanta as a walkable city. Getting to a transit station without a car still poses a challenge, he notes, and one of the reasons Atlantic Station remains overlooked is that people don't notice its shops from the road.
"I am an Atlanta native and this has never been a walking, pedestrian city," he says. "Being more environmentally aware is something we are still getting used to. I am sure the Midtown Mile will be a tremendous success, but it's a matter of being patient."
As rattled by the current credit crunch as anyone in the country, Atlanta's investment sales brokers remain apprehensive. In the second quarter of 2007, the city's retail properties traded at an average cap rate of 6.9 percent, above the national average of 6.3 percent, while posting an average price of $168 per square foot, 11 percent below the national average of $182 per square foot, according to Real Capital Analytics.
"The uncertainty in the debt market is affecting some of our buyers, so it's a wait-and-see scenario," says Del Creviston, senior investment advisor with the Atlanta office of brokerage firm Sperry Van Ness, who adds that he still managed to close three deals within one week this month.
"Cap rates have been on the rise 100 basis points to 200 basis points over the last 60 days," Creviston says.
Market statistics bear this out. In the second quarter of 2007, sales of single-tenant retail properties rose 90 percent compared to the velocity experienced during the same period last year, according to Marcus & Millichap. Cap rates, however, remained close to last year's low-7 percent range.
Population in 2000: 4,247,981
Population in 2007: 5,305,098
Change 2000-2007: 24.9%
Households in 2000: 1,554,154
Households in 2007: 1,943,480
Change 2000-2007: 25.1%
Source: Pitney Bowes MapInfo
(As of July 2007)
Atlanta Metropolitan Area: 4.7%
Georgia: 4.9%
National: 4.6%
Source: Pitney Bowes MapInfo


text:
You have no discounts. Click here to get some.
Florida St -21 vs Miami-Fl:Biggest spread in history between undefeated Top 10 teams this late in season!Only TWO other instances of a double digit favorite when two undefeated Top 10 teams play this late in the season:*Texas favored by 12 hosting Oklahoma State (10/25/2008)*Miami-Fl favored by 11 vs. Ohio State (2002 BCS Title Game)[database goes all the way back to 1980]Does this fact make you like the favorite or underdog?
Login to reply to this post. Not a member? Joining Pregame.com is fast and free.
No chance I can back the dog here. I have FSU -20.5. Having said that, if the line does somehow hit +24 I will try and middle it.
hmmm, texas won by 4
ohio st won outright by 7 in double ot
I still like the favourite in this one
Here's the deal. the look ahead line was 14 at the LVH on Friday morning, so FSU is now 7 points better after one game?
I do like the Hurricanes, but I do think that they are way over-ranked.....shouldn't be a Top 10 match-up (and probably isn't really).....
Nope I have FSU#2 93.5 Mia#18 78.5 in my ratings.
"FSU could be a national champ team..they are #2 and #3 in the polls"...Heisman QbB..Viscious defense..."beat Clemson bad in Clemson on National Tv"......."Eww Miami stinks"...yea they didnt beat anybody..almost got beat by Wake Forest..."Even if they do win they wont play for a title"...."u gotta bet FSU"...they prob blowout Miami...."Miami is overrated"........They set the line at 21 for a conf game, 2 undefeated teams....these teams are rivals...21points...I forgot Clemson defense is better than MIAMI..wait i think Miami defense is # 11 in the nation.....I like MIAMI getting the points...16.5 i think is true..they seem to be getting twice..if not 3 times..if u back FSU....granted FSU can win and cover...and so can MIA
Anytime you get two teams with identical records, and one team laying 7 or more pts, for the most part, please take the favorite. Seen it time and time again this season. This means that the two teams are not equal. If they were, the spread wouldnt be so big. Vegas just wants to split that action by giving Miami 3TDS. Florida st will blow them out. Ez...!!
Bruno Bets said:
I do like the Hurricanes, but I do think that they are way over-ranked.....shouldn't be a Top 10 match-up (and probably isn't really).....
Agree, the Canes is far from being a top 10 team. FL State will expose it this Saturday
Just my thoughts on this game..
Personally I thought this line would have opened in the 17 point range even though I think Miami's ranking is misleading. Yes they are undefeated, also a very weak schedule thus far. Miami was very fortunate against Florida, I remember that game well having Florida. Several very poor timed turnovers. The final score against an average GT team is misleading as well, that was a close game until GT took a poop in the fourth. Miami then needed fourth QTR comeback wins to beat two poor teams in UNC and Wake. I credit them for coming back, but really it should not have come to that. Morris to me has not been good this year, his receiving group is not as good as it has been. Miami WR's could have trouble with a physical Florida St secondary that could be one of the best in the country.
Having said that I could see Miami staying in this game if they commit to a very conservative approach on offense and the defense finds a way to get to the Florida st QB. Miami has the talent on defense to give them a chance, but they are not going to be able to hold Florida St down the whole game. They have some guys on the D line that maybe can find a way to pressure the QB and force some bad decisions. I think in Miami's last two games the coaching staff seemed to be not wanting to give QB Morris too many opportunities to make bad decisions. They were pretty conservative against Wake, probably because they knew they could be. I have always liked the Miami's coach defensive approach. He wants to put his defense in positions to succeed, and does everything to keep his teams in the game.
I personally thought Clemson was going to give Florida St a much better challenge, thought Florida St would win a close game. I hammered Clemson on the in-running when they were down early in the first QTR. At the time I felt great about getting Clemson +17.5 before the first QTR even ended. Feeling like Clemson was just a little unlucky early, but of course we know how that ended. Clemson though played right into what Florida St wanted by not having or really attempting any running game and forcing Boyd into some tough plays. Boyd also obviously made some really bad decisions that just kept the Florida st steamroll going. I have to think Miami's approach in this game is going to be to run early and often to try and keep Florida St off the field. I expect them to try and keep this game much slower than what Florida St wants.
I also take into account the fact that most of the country saw that Florida St, Clemson game when it was only a 3.5 to 5 point line, this line seems to be a bit of an over-reaction in that aspect. What if Clemson and Florida St could play again at Florida St? What would the line be? What would a Miami at Clemson line be? I do not really know I just think that there is some inflation in this line. The odds-makers have been really trying to catch up to this Florida st team as they have been a covering machine (just missed the cover last week, depending on your line). Let us not forget that they really have not played that tough of a schedule (about 32 on SOS rankings). But they have been just destroying teams and covering these large spreads. I am of the belief that the books are still trying to catch up so they are adding that into the line for the favorite.
Bottom line, I think Florida St wins but does not cover 22. I do not think Miami is a top 10 team, but I do think they have a top ten QB and some players that will play with a chip on their shoulders. I like both coaches, but think the story after this game will be how Miami's D kept the Florida St QB in check (relatively). The books have not been able to make the Florida st lines high enough, they are continuing to try and it still seems to be one sided on the favorite. This will be the best Defensive line that Florida St has faced, probably the best Defense. Miami has 3 guys on the D line that are very good and won't be pushed around easily (I think they are all playing although have not really looked into it). They may find a way to get to the Florida St QB and force him into some bad decisions, lets not forget that he is still young and has not really had to perform in a tough spot.
Your share has been sent.
Future Game
Bet Type:
Full Pick Details
Pick Name
Odds: Odds
Picked: Stamp
Join the Contest


text:
Who Should Be Crowned the SuicideGirl of the Year for 2012?
Every day, we feature one of the fantastic and fascinating SuicideGirls. Every single girl is incredibly popular but it's time to choose just one winner -- the SuicideGirl of the Year.
We've picked the ten most popular SuicideGirls from 2012. Soya, our returning champion, has competition from nine other lovely ladies including the very popular Kemper Suicide. Click on each girl's name to see their original post from this year.
The voting ends December 31st, 2012 at 11:59 pm EST and the winning girl gets interviewed and featured on this website on the first of the year. Fans can vote once per hour, so keep coming back to make sure your favorite SuicideGirl wins!
Who will emerge as the queen killer for 2012?
Meet Kemper, a SuicideGirl who spends most of her free time searching for the "mythical clitoris." Can we join the search party?
Meet Babilina – a 26-year-old Brazilian who's into tequila, whiskey, vodka, and sex – specifically in a car. She didn't say anything about it being a rental, so we're off to Hertz.
Lass, the 20-year-old bookworm from Scotland, has been featured numerous times on the website but really not enough in our opinion. If only we could control something like that.
Meet Felina — a SuicideGirl who's into coffee, drawing, photography, and listening to The Doors, Johnny Cash, and Queens of the Stone Age. Is it too much to state Felina's the Queen of the Bone Age? Yeah. Too much.
Meet Brulee, a 20-year-old "total stoner" from Ohio who loves dreads (duh) and gets all frowny face when those ASPCA commercials come on. Us, too, Brulee. Us, too.
The returning champion, this SuicideGirl came back even stronger in 2012.
Meet Bessy – a 21-year-old SuicideGirl who's into IT (information technology, not the Stephen King monster, although, she's probably into that, too).
Meet Dimples, a Suicide Girl from Chicago who loves her sock monkey and isn't quite sure what the term "drug free" means.
Today's SuicideGirl is rainbow-haired Kieve. She's a Colombian stylist who loves pizza and Batman.
Meet Katherine, a SuicideGirl who calls herself a complete drunk, makes her own happiness and thinks she eats way too much junk food.


text:
If you have an account with us, please log in.
Forgot Your Password?
Don't have an account?Sign Up
Shopping Cart
You have no items in your shopping cart.
12 Item(s)
View as: Grid List
You have no items to compare.
Susu & Makanan Bayi
Popok Bayi
Peralatan Mandi
Sign Up For Newsletter
Follow Us
Sudah Berkunjung ke SusuMurahOnlineGabung bersama kami dan dapatkan penawaran menarik


text:
Office of the Provost
Davis Baird
Provost and Vice President for Academic Affairs
As Provost and Vice President for Academic Affairs, Davis Baird is the chief academic officer of Clark University. Reporting to the President, the Provost oversees all undergraduate and graduate academic programs, as well as athletics, student affairs, sponsored research, university libraries, and the registrar's office.
Baird is a principal architect of Clark's new model for undergraduate education, Liberal Education and Effective Practice, and is also working on a significant expansion of Clark's graduate studies footprint. He was a primary driver behind the creation and launch of the Office of Diversity and Inclusion.
Davis Baird came to Clark in 2010 from the University of South Carolina, where he was Dean of the South Carolina Honors College for five years and the Louise Fry Scudder Professor in the Philosophy Department since 2004. Prior to his time as dean, he chaired the Philosophy Department for 13 years. Before his time at South Carolina, Baird was Visiting Assistant Professor at the University of Arizona, where he taught for a year after receiving his Ph.D. in Philosophy from Stanford University. He also holds a Master's degree in Philosophy of Science from Stanford, and a Bachelor's degree in Mathematics and Philosophy from Brandeis University.
Baird's research interest is the philosophy of science and technology. In the area of nanotechnology, as Principal Investigator, he has received more than $3.0 million in funding from the National Science Foundation and the Carnegie Foundation. He is also pursuing research on the commercialization of scientific knowledge and on the function of scientific images.
Prior to his work on nanotechnology, Baird's research focused on the history and philosophy of scientific instruments. He is interested in the epistemology of scientific instruments, or how the things that we make express our knowledge. He is the author of Thing Knowledge: A Philosophy of Scientific Instruments (University of California Press, 2004), which won the 2006 Paul Bunge Prize. As the son of Walter Baird, co-founder of one of the early developers of spectrographic instrumentation, he follows a familial interest.
Baird is also the author of Inductive Logic: Inferring the Unknown (Prentice Hall, 1992; Pearson Publishing, 1999) and is co-editor of Discovering the Nanoscale (IOS press, 2004) and of two collections published in the Boston Studies in the Philosophy of Science series: Heinrich Hertz: Classical Physicist, Modern Philosopher (Kluwer, 1994) and Philosophy of Chemistry: Synthesis of a New Discipline (Spring, 2006).
Contact Information
212 Geography Building
Clark University
950 Main Street
Worcester, MA 01610-1477
(508) 793-7673
Fax: (508) 793-8834
Email: email@example.com